Ambit Biosciences' P2P Acquisition

Ambit Biosciences raised a round of funding on September 29, 2014. Investors include Daiichi Sankyo.

Ambit Biosciences is a biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indicat…

Articles about Ambit Biosciences' P2P Acquisition: